Compare IMUX & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMUX | SMTI |
|---|---|---|
| Founded | 2016 | 1982 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.6M | 182.6M |
| IPO Year | 2013 | 2008 |
| Metric | IMUX | SMTI |
|---|---|---|
| Price | $1.01 | $20.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $4.50 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 2.1M | 60.4K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,586,976.00 |
| Revenue This Year | N/A | $17.31 |
| Revenue Next Year | N/A | $12.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.47 |
| 52 Week Low | $0.51 | $16.05 |
| 52 Week High | $1.51 | $35.70 |
| Indicator | IMUX | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 42.29 | 62.39 |
| Support Level | $0.62 | $20.12 |
| Resistance Level | $1.17 | $21.14 |
| Average True Range (ATR) | 0.11 | 1.04 |
| MACD | -0.03 | 0.46 |
| Stochastic Oscillator | 14.06 | 75.76 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.